ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

sacituzumab govitecan (16) vs trastuzumab deruxtecan (16)26 active2017–2035
sacituzumab govitecantrastuzumab deruxtecan
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedTerminated
'17
'19
'21
'23
'25
'27
'29
'31
'33
'35
sacituzumab govitecan
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCP2
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCP2
Scalp Cooling in MBCP2
EVOKE-01P3
ELEVATE TNBCP2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)P2
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)P3
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerP2
Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyP2
ASCENT-GYN-01P3
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)P2
Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2
OASISP2
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerP3
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareP3
SCARLET-ICEP2
trastuzumab deruxtecan
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)P2
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)P2
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]P3
DAISYP2
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)P2
DG-03P2
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerP2
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)P3
DG-06P2
Scalp Cooling in MBCP2
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)P2
Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)P3
TDXdoseP4
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerP2
MEGA-TACT-BC3P3

Upcoming readouts

19 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.